Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J. Forsman LD, et al. Among authors: giske cg. Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068. Clin Infect Dis. 2019. PMID: 30561569
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T. Juréen P, et al. Among authors: giske cg. J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17. J Clin Microbiol. 2010. PMID: 20237102 Free PMC article.
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. Angeby KA, et al. Among authors: giske cg. J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23. J Antimicrob Chemother. 2010. PMID: 20332195
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Magiorakos AP, et al. Among authors: giske cg. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. Clin Microbiol Infect. 2012. PMID: 21793988 Free article.
Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.
Angeby K, Giske CG, Juréen P, Schön T, Pasipanodya JG, Gumbo T. Angeby K, et al. Among authors: giske cg. Antimicrob Agents Chemother. 2011 Sep;55(9):4492-3; author reply 4493. doi: 10.1128/AAC.00232-11. Antimicrob Agents Chemother. 2011. PMID: 21849570 Free PMC article. No abstract available.
268 results